cidofovir
Cytomegalovirus Retinitis
National Center for Research Resources (NCRR)Small moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cytomegalovirus Retinitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ganciclovir | Phase 4 | A |
Foscarnet | Phase 2 | BBB |
Probenecid | Phase 4 | BB |
Sevirumab | Phase 2 | BB |
Sargramostim | Phase 3 | BB |
DNA, D(P-THIO)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G), EICOSASODIUM SALT | Phase 2 | B |
Valganciclovir | N/A | D |
ZIDOVUDINE | N/A | D |
Same molecule, other indications
cidofovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →